Analytical Data
-
Gene name
KIR3DL1
- Application
-
Alternative Names
CD158E; HLA-BW4-specific inhibitory NK cell receptor; CD158 antigen-like family member E; Natural killer-associated transcript 3; p70 NK receptor CL-2/CL-11
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43629
-
Expression Region
Pro164~Arg437
-
Molecular Weight
66kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KIR3DL1 is a member of the Killer Immunoglobulin-like Receptor (KIR) family, primarily expressed on natural killer (NK) cells and a subset of T cells. It plays a crucial role in the immune response by recognizing specific ligands, such as HLA-B alleles, thereby influencing the activation and inhibition of NK cell functions. Studies have linked KIR3DL1 to various immune-related disorders, including autoimmune diseases, viral infections, and cancer, making it a significant target for therapeutic interventions. The heterogeneity of KIR3DL1 expression among individuals, along with its polymorphic nature, has implications for transplant outcomes and disease susceptibility. Consequently, recombinant protein studies of KIR3DL1 enhance our understanding of its structural and functional characteristics, paving the way for potential clinical applications, such as immunotherapy or vaccine development. The investigation of KIR3DL1 recombinant proteins facilitates the exploration of its ligand interactions and signaling pathways, offering insights into its role in modulating immune responses and its potential as a biomarker for various diseases.
